Advertisement

Hormones

, Volume 14, Issue 1, pp 134–141 | Cite as

Autonomic nervous system and cardiovascular risk assessment during one year of growth hormone replacement therapy in adults with growth hormone deficiency

  • Mara Boschetti
  • Massimo Casu
  • Sara Moretti
  • Claudia Teti
  • Valeria Albanese
  • Manuela Albertelli
  • Giovanni Murialdo
  • Francesco Minuto
  • Diego Ferone
Research paper
  • 4 Downloads

Abstract

OBJECTIVE: This prospective study aimed to evaluate the impact of growth hormone deficiency (GHD) on cardiac autonomic tone and on cardiovascular risk and the changes after 12 months of GH replacement therapy (GHRT). GHD is associated with increased cardiovascular morbidity and mortality. This has been attributed to increased markers of cardiovascular risk and to abnormalities of both the cardiac and peripheral autonomic nervous systems. The autonomic cardiac nervous system (ACNS) can be indirectly evaluated by analysis of heart rate variability (HRV) in clinostatism and orthostatism. DESIGN: We compared 14 GHD patients at baseline and after 12 months of GHRT and 17 healthy controls. We analyzed a number of cardiovascular risk factors and we used analysis of HRV during the Tilt Test that identified high frequency (HF) and low frequency (LF), representing parasympathetic and sympathetic activity, respectively. RESULTS: Compared with the control group, in either clinostatism or in orthostatism our patients showed a significantly lower value of LF (P=0.047; P=0.004, respectively), whereas HF was significantly reduced in orthostatism (P=0.037), and indicatively in clinostatism (P=0.065). These values remained unchanged after 12 months of GHRT. No statistically significant differences were found between the LF/HF ratio in untreated and treated patients. In GHD patients, there was a significant reduction of cardiovascular risk in 12 months of replacement therapy (P=0.002). CONCLUSIONS: Our study highlights the absence of sympathovagal imbalance in GHD patients; GHRT does not change ACNS during the first year of GH treatment but it reduces the absolute cardiovascular risk in these patients.

Key words

Autonomic nervous system GHD IGF-I 

References

  1. 1.
    Rosen T, Bengtsson BA, 1990 Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336: 285–288.CrossRefGoogle Scholar
  2. 2.
    Bates AS, Van’t HW, Jones PJ, Clayton RN, 1996 The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab 81: 1169–1172.PubMedGoogle Scholar
  3. 3.
    Tomlinson JW, Holden N, Hills RK, et al, 2001 Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 357: 425–431.CrossRefGoogle Scholar
  4. 4.
    Cuneo RC, Salomon F, McGauley GA, Sonksen PH, 1992 The growth hormone deficiency syndrome in adults. Clin Endocrinol Oxf 37: 387–397.CrossRefGoogle Scholar
  5. 5.
    Jorgensen JO, Pedersen SA, Thuesen L, et al, 1989 Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet 1: 1221–1225.CrossRefGoogle Scholar
  6. 6.
    Rosen T, Eden S, Larson G, Wilhelmsen L, Bengtsson BA 1993 Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinol Copenh 129: 195–200.PubMedGoogle Scholar
  7. 7.
    De Boer H, Blok GJ, Voerman HJ, Phillips M, Schouten JA 1994 Serum lipid levels in growth hormone-deficient men. Metabolism 43: 199–203.CrossRefGoogle Scholar
  8. 8.
    Cuneo RC, Salomon F, Watts GF, Hesp R, Sonksen PH, 1993 Growth hormone treatment improves serum lipids and lipoproteins in adults with growth hormone deficiency. Metabolism 42: 1519–1523.CrossRefGoogle Scholar
  9. 9.
    Boschetti M, Goglia U, Teti C, et al, 2008 Replacement therapy and cardiovascular diseases. J Endocrinol Invest 31: 85–90.CrossRefGoogle Scholar
  10. 10.
    Salomon F, Cuneo RC, Umpleby AM, Sonksen PH, 1994 Interactions of body fat and muscle mass with substrate concentrations and fasting insulin levels in adults with growth hormone deficiency. Clin Sci Colch 87: 201–206.CrossRefGoogle Scholar
  11. 11.
    Gomberg-Maitland M, Frishman WH, 1996 Recombinant growth hormone: a new cardiovascular drug therapy. Am Heart J 132: 1244–1262.CrossRefGoogle Scholar
  12. 12.
    Lombardi G, Colao A, Ferone D, Marzullo P, Orio F, Longobardi S, Merola B, 1997 Effect of growth hormone on cardiac function. Horm Res 48: Suppl 4: 38–42. ReviewCrossRefGoogle Scholar
  13. 13.
    Leong KS, Mann P, Wallymahmed M, MacFarlane IA, Wilding JP, 2001 The influence of growth hormone replacement on heart rate variability in adults with growth hormone deficiency. Clin Endocrinol (Oxf) 54: 819–826.CrossRefGoogle Scholar
  14. 14.
    Sverrisdottir YB, Elam M, Herlitz H, Bengtsson BA, Johannsson G, 1998 Intense sympathetic nerve activity in adults with hypopituitarism and untreated growth hormone deficiency. J Clin Endocrinol Metab 83: 1881–1885.PubMedGoogle Scholar
  15. 15.
    Beshyah SA, Johnston DG, 1999 Cardiovascular disease and risk factors in adults with hypopituitarism. Clin Endocrinol (Oxf) 50: 1–15.CrossRefGoogle Scholar
  16. 16.
    Colao A, Di Somma C, Rota F, et al, 2005 Short-term effects of growth hormone (GH) treatment or deprivation on cardiovascular risk parameters and intima-media thickness at carotid arteries in patients with severe GH deficiency. J Clin Endocrinol Metab 90: 2056–206.CrossRefGoogle Scholar
  17. 17.
    Pfeifer M, Verhovec R, Zizek B, Prezel J, Poredos P, Clayton RN, 1999 Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults. J Clin Endocrinol Metab 84: 453–457.PubMedGoogle Scholar
  18. 18.
    Colao A, Di Somma C, Cuocolo A, et al, 2001 Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients with GH deficiency. J Clin Endocrinol Metab 86: 1874–1881.PubMedGoogle Scholar
  19. 19.
    Amato G, Carella C, Fazio S, et al, 1993 Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. J Clin Endocrinol Metab 77: 1671–1676.PubMedGoogle Scholar
  20. 20.
    Ezzat S, Fear S, Gaillard RC, et al, 2002 Gender-specific responses of lean body composition and non-gender-specific cardiac function improvement after GH replacement in GH-deficient adults. J Clin Endocrinol Metab 87: 2725–2733.CrossRefGoogle Scholar
  21. 21.
    Malliani A, Lombardi F, Pagani M, Cerutti S, 1994 Power spectral analysis of cardiovascular variability in patients at risk for sudden cardiac death. J Cardiovasc Electrophysiol 5: 274–286.CrossRefGoogle Scholar
  22. 22.
    Vanoli E, Schwartz PJ, 1990 Sympathetic-parasympathetic interaction and sudden death. Basic Res Cardiol 85: Suppl 1: 305–321.PubMedGoogle Scholar
  23. 23.
    Zipes DP, Heger JJ, Prystowsky EN, 1983 Pathophysiology of arrhythmias: clinical electrophysiology. Am Heart J 106: 812–828.CrossRefGoogle Scholar
  24. 24.
    Kjellgren O, Gomes JA, 1993 Heart rate variability and baroreflex sensitivity in myocardial infarction. Am Heart J 125: 204–215.CrossRefGoogle Scholar
  25. 25.
    Singh N, Mironov D, Armstrong PW, Ross AM, Langer A, 1996 Heart rate variability assessment early after acute myocardial infarction. Pathophysiological and prognostic correlates. GUSTO ECG Substudy Investigators. Global Utilization of Streptokinase and TPA for Occluded Arteries. Circulation 93: 1388–1395.CrossRefGoogle Scholar
  26. 26.
    Lombardi F, Mortara A, 1998 Heart rate variability and cardiac failure. Heart 80: 213–214.CrossRefGoogle Scholar
  27. 27.
    Osterhues HH, Kochs M, Hombach V, 1998 Time-dependent changes of heart rate variability after percutaneous transluminal angioplasty. Am Heart J 135: 755–761.CrossRefGoogle Scholar
  28. 28.
    Spallone V, Uccioli L, Menzinger G, 1995 Diabetic autonomic neuropathy. Diabetes Metab Rev 11: 227–257.CrossRefGoogle Scholar
  29. 29.
    Spallone V, Menzinger G, 1997 Autonomic neuropathy: clinical and instrumental findings. Clin Neurosci 4: 346–358.CrossRefGoogle Scholar
  30. 30.
    Kleiger RE, Stein PK, Bigger JT Jr, 2005 Heart rate variability: measurement and clinical utility. Ann Noninvasive Electrocardiol 10: 88–101.CrossRefGoogle Scholar
  31. 31.
    Andersson IJ, Barlind A, Nystrom HC, et al, 2004 Reduced sympathetic responsiveness as well as plasma and tissue noradrenaline concentration in growth hormone transgenic mice. Acta Physiol Scand 182: 369–378.CrossRefGoogle Scholar
  32. 32.
    Resmini E, Casu M, Patrone V, et al, 2006 Sympathovagal imbalance in acromegalic patients. J Clin Endocrinol Metab 91: 115–120.CrossRefGoogle Scholar
  33. 33.
    Leong KS, Mann P, Wallymahmed M, MacFarlane IA, Wilding JP, 2000 Abnormal heart rate variability in adults with growth hormone deficiency. J Clin Endocrinol Metab 85: 628–633.PubMedGoogle Scholar
  34. 34.
    Scott EM, Greenwood JP, Stoker JB, Mary DA, Gilbey SG 2002 Sympathetic nerve hyperactivity is associated with increased peripheral vascular resistance in hypopituitary patients with growth hormone deficiency. Clin Endocrinol 56: 759–763.CrossRefGoogle Scholar
  35. 35.
    Sverrisdóttir YB, Elam M, Caidahl K, Söderling AS, Herlitz H, Johannsson G, 2003 The effect of growth hormone (GH) replacement therapy on sympathetic nerve hyperactivity in hypopituitary adults: a double-blind, placebo-controlled, crossover, short-term trial followed by long-term open GH replacement in hypopituitary adults. J Hypertens 21: 1905–1914.CrossRefGoogle Scholar
  36. 36.
    Barron HV, Lesh MD, 1996 Autonomic nervous system and sudden cardiac death. J Am Coll Cardiol 27: 1053–1060.CrossRefGoogle Scholar
  37. 37.
    Tanriverdi F, Eryol NK, Atmaca H, et al, 2005 The effects of 12 months of growth hormone replacement therapy on cardiac autonomic tone in adults with growth hormone deficiency. Clin Endocrinol 62: 706–712.CrossRefGoogle Scholar
  38. 38.
    Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology, 1996 Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation 93: 1043–1065.CrossRefGoogle Scholar
  39. 39.
    Task Force of the European society of Cardiology and The North American Society of Pacing and Electrophysiology, 1996 Heart rate variability. Guidelines. Standards of measurements, physiological interpretation and clinical use. European Heart Journal 17: 354–381.CrossRefGoogle Scholar
  40. 40.
    Menotti A, Lanti M, Agabiti-Rosei E, et al, 2005 Riskard 2005: new tools for prediction of cardiovascular disease risk derived from Italian population studies. Nutr Metab Cardiovasc Dis 15: 426–440.CrossRefGoogle Scholar
  41. 41.
    Proceedings of the IV National Conference of cardiovascular prevention. G Ital Cardiol (Rome) 15: 253–263.Google Scholar
  42. 42.
    Cittadini A, Strömer H, Vatner DE, et al, 1997 Consequences of growth hormone deficiency on cardiac structure, function, and beta-adrenergic pathway: studies in mutant dwarf rats. Endocrinology 138: 5161–5169.CrossRefGoogle Scholar
  43. 43.
    Abdu TA, Elhadd TA, Buch H, Barton D, Neary R, Clayton RN, 2004 Recombinant GH replacement in hypopituitary adults improves endothelial cell function and reduces calculated absolute and relative coronary risk. Clin Endocrinol 61: 387–393.CrossRefGoogle Scholar

Copyright information

© Hellenic Endocrine Society 2015

Authors and Affiliations

  • Mara Boschetti
    • 1
    • 3
  • Massimo Casu
    • 2
  • Sara Moretti
    • 1
  • Claudia Teti
    • 1
  • Valeria Albanese
    • 1
  • Manuela Albertelli
    • 1
    • 3
  • Giovanni Murialdo
    • 2
  • Francesco Minuto
    • 1
    • 3
  • Diego Ferone
    • 1
    • 3
  1. 1.Section of Endocrinology, Department of Internal Medicine and Medical SpecialtiesUniversity of GenoaGenoaItaly
  2. 2.Section of Internal Medicine, Department of Internal Medicine and Medical SpecialtiesUniversity of GenoaGenoaItaly
  3. 3.Center of Excellence for Biomedical ResearchUniversity of GenoaGenoaItaly

Personalised recommendations